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The central sensitization syndrome (CSS) encompasses disorders with overlapping
symptoms in a structural pathology spectrum ranging from persistent nociception
[e.g., osteoarthritis (OA)] to an absence of tissue injuries such as the one presented
in fibromyalgia (FM) and myofascial pain syndrome (MPS). First, we hypothesized that
these syndromes present differences in their cortical excitability parameters assessed
by transcranial magnetic stimulation (TMS), namely motor evoked potential (MEP),
cortical silent period (CSP), short intracortical inhibition (SICI) and short intracortical
facilitation (SICF). Second, considering that the presence of tissue injury could be
detected by serum neurotrophins, we hypothesized that the spectrum of structural
pathology (i.e., from persistent nociception like in OA, to the absence of tissue injury like
in FM and MPS), could be detected by differential efficiency of their descending pain
inhibitory system, as assessed by the conditioned pain modulation (CPM) paradigm.
Third, we explored whether brain-derived neurotrophic factor (BDNF) had an influence
on the relationship between motor cortex excitability and structural pathology. This
cross-sectional study pooled baseline data from three randomized clinical trials. We
included females (n = 114), aged 19–65 years old with disability by chronic pain
syndromes (CPS): FM (n = 19), MPS (n = 54), OA (n = 27) and healthy subjects (n = 14).
We assessed the serum BDNF, the motor cortex excitability by parameters the TMS
measures and the change on numerical pain scale [NPS (0–10)] during CPM-task. The
adjusted mean (SD) on the SICI observed in the absence of tissue injury was 56.36%
lower than with persistent nociceptive input [0.31(0.18) vs. 0.55 (0.32)], respectively.
The BDNF was inversely correlated with the SICI and with the change on NPS (0–10)
during CPM-task. These findings suggest greater disinhibition in the motor cortex and
the descending pain inhibitory system in FM and MPS than in OA and healthy subjects.
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Likewise, the inter-hemispheric disinhibition as well as the dysfunction in the descending
pain modulatory system is higher in chronic pain without tissue injury compared to a
structural lesion. In addition, they suggest that a greater level of serum BDNF may be
involved in the processes that mediate the disinhibition of motor cortex excitability, as
well as the function of descending inhibitory pain modulation system, independently of
the physiopathology mechanism of musculoskeletal pain syndromes.
Keywords: short intracortical inhibition, brain-derived neurotrophic factor, central sensitization, conditioned pain
modulation, osteoarthritis, fibromyalgia, myofascial pain syndrome
INTRODUCTION
A central sensitivity syndrome (CSS) is a cluster of symptoms
including psychological distress, sleep disturbances, fatigue,
pain, allodynia, hyperalgesia, and expansion of the receptive
field (Yunus, 2007, 2008), which overlap with many chronic
pain disorders. Despite the substantial overlapping, there
is no consensus on the presence of these symptoms and
structural pathology. For instance, in fibromyalgia (FM), chronic
tensional headache and myofascial pain syndrome (MPS) the
evidence of structural pathology is scarce. In contrast, in other
conditions like osteoarthritis (OA), there is strong evidence
of anatomic structural pathology that accounts for persistent
nociceptive input. Nonetheless, irrespective of the amount of
visible injury, these chronic pain conditions share a cluster
of symptoms that support the hypothesis of the presence of
central sensitization (CS) phenomenon. This neuronal event
comprises an abnormal state of responsiveness for nociceptor
stimuli. Thus, the pain arises as a consequence of changes
within the central nervous system (CNS) that amplifies the
response to nociceptive inputs across many organ systems and
fails to suppress noise signals (Woolf and Salter, 2000; Ji et al.,
2003).
At the cellular level, the CS comprises an impaired function
of neurons and circuits in nociceptive pathways, in which exist
increased membrane excitability, synaptic efficacy, or reduced
inhibition (Latremoliere andWoolf, 2009). Sensitized neurons of
the spinal dorsal horn exhibit increased spontaneous activity and
response to subthreshold stimulation, reduction in the threshold
for activation, and an enlargement of their receptive fields
(Latremoliere and Woolf, 2009).
Thus, CSS pain arises from different abnormal mechanisms,
including increased presynaptic release of excitatory
neurotransmitters that will, in turn, elicit a greater postsynaptic
response, by increasing the excitability of the postsynaptic
membrane (Woolf et al., 1994; Craig, 2003). Then, changes in
the microglia, astrocytes, gap junctions and gene transcription,
contribute to the maintenance of this general state of excitation.
Moreover, as part of the spinal microglial activation, the
brain-derived neurotrophic factor (BDNF) is released, further
contributing to the induction and maintenance of the CS
(Trang et al., 2011).
Besides clinical complaints, the CSS also shares
pathophysiological mechanisms. In OA, lower pain threshold
and punctual hyperalgesia has been shown in areas of
referred pain rather than on the original area of tissue
injury (O’Driscoll and Jayson, 1975; Bajaj et al., 2001),
which has been thought to reflect brainstem activation, as
shown by functional magnetic resonance imaging (fMRI;
Gwilym et al., 2009). In FM, the CS has been associated
with the widespread reduction in thermal and mechanical
pain thresholds (Gibson et al., 1994), inducing temporal
summation, muscular hyperalgesia and pain, which are
attenuated experimentally with the use of ketamine (Graven-
Nielsen et al., 2000). Similarly, the persistent muscular
tension experienced in the MPS has been hypothesized to
induce CS (Fernández-de-las-Peñas et al., 2009), which could
progressively produce the lead changes in the SNC. Although
the BDNF is a common key player in the CS process, our
research team recently showed that its serum levels might
differ among chronic pain syndromes (CPS) (Deitos et al.,
2015). In fact, the BDNF is a neurotrophic factor capable
of strengthening glutamatergic synapses, while it weakens
GABAergic synapses. The increase of this neurotrophic
factor inverts the polarity of GABA currents in dorsal horn
neurons (Coull et al., 2005). Thereby the GABAergic system
loses the capacity to downregulate of the Cl-cotransporter
K+-Cl− exporter (KCC2) expression in the dorsal horn (Rivera
et al., 2002; Zhang et al., 2008). Thus, the accumulation
intracellular of Cl− limits the GABAergic inhibitory effect
on these nociceptors, thereby promoting the disinhibition
(Latremoliere and Woolf, 2009), which results in a persistent
and amplified response to nociceptive inputs and fails to
suppress noise signals (Woolf and Salter, 2000; Ji et al., 2003).
Although the cross-talk among BDNF and chronic pain is
a complex phenomenon, and the underlying mechanisms
responsible for such observations remain poorly understood, the
differential BDNF levels might be utility in distinguishing CS
syndromes with and without structural pathology (Deitos et al.,
2015).
Considering that the CSS is the utmost clinical picture of
dysfunctional neuronal circuits where the defective inhibitory
function stands out, it is reasonable to consider the use of
neuronal inhibition indexes to increase our mechanistically
knowledge about the underlying neural substrates of CSS.
Fortunately, it is nowadays possible to clinically assess the
motor intracortical inhibition (ICI) and probing neural
plasticity (Schwenkreis et al., 2011) using the motor cortex
excitability by transcranial magnetic stimulation (TMS)
paradigms. Accordingly, in the neuropathic pain compared
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to healthy controls (HCs) the repetitive transcranial magnetic
stimulation (rTMS) improved the cortical disinhibition indexed
by the ICI and by a shorter cortical silent period (CSP;
Lefaucheur et al., 2006). Similar results were observed in
other chronic pain conditions, such as in FM (Salerno et al.,
2000) and complex regional pain (Schwenkreis et al., 2003).
While in healthy subjects’ experimental pain using capsaicin,
the rTMS applied over the dorsolateral prefrontal cortex
(DLPFC) decreased the short intracortical inhibition (SICI;
Fierro et al., 2010) and induced a significant anti-nociceptive
effect in the capsaicin pain model (Brighina et al., 2011).
Thereby, this set of findings suggest that the TMS, permit us
modulate and also assess the state of the balance of excitatory
and inhibitory system involved in the physiopathology of
the CSS, which is a fundamental process to develop and
maintain the CPS.
Therefore, the present study aims to explore tools to assess
clinically some of the mechanisms likely associated with the
CS. We evaluated the cortical excitability, the function in the
descending pain modulatory system, and their relationships
with the BDNF in three CS syndromes of chronic pain with
different pieces of evidence of tissue injury: OA, FM, and MPS.
Thus, we explored three hypotheses. First, we hypothesized
that these syndromes present differences in their cortical
excitability parameters assessed by TMS, namely motor evoked
potential (MEP), CSP, SICI and short intracortical facilitation
(SICF). Second, considering that the CS in the absence of
tissue injury could be detected by serum neurotrophins, we
hypothesized that the spectrum of structural pathology (i.e., from
persistent nociception like in OA, to the absence of tissue
injury like in FM and MPS), could be detected by differential
efficiency of their descending pain inhibitory system, as
assessed by the conditioned pain modulation (CPM) paradigm.
Third, we explored whether BDNF had an influence on the
relationship between motor cortex excitability and structural
pathology.
MATERIALS AND METHODS
Design Overview, Settings, and
Participants
This protocol was approved by the Institutional Ethics
Committee at the Hospital de Clínicas de Porto Alegre (HCPA;
application no. 1005-55, Post-Graduate Research Group). All
of the trials ran their respective protocols with the approval of
the HCPA Ethics Committee and obtained written informed
consent from all subjects. We conducted a cross-sectional study
pooling baseline data from three clinical trials. The sample
involved women with chronic pain conditions associated with
CS syndromes but without evidence of structural pathology
(FM NCT01904097 and MPS NCT01964729), and chronic
pain conditions with CS symptoms due to known organic
pathology (i.e., OA NCT01747070). Details of the inclusion
of each study can be seen in Figure 1. All subjects were
recruited by directly contacting them from the institutional
chronic pain clinic, by referrals from other clinic units, and
through media advertising. Besides their particular criteria, all
trials excluded subjects who failed to understand Brazilian
Portuguese.
The baseline data from the samples of three experiments
conducted in our institution were retrieved. All the studies used
the 100 mm visual analog scale (VAS) for pain, ranging from
no pain (0 mm) to the worst pain imaginable (100 mm). Only
subjects that reported pain equal or higher than 40 mm in
the VAS [i.e., moderate or severe pain (Palos et al., 2006)] for
more than 3 months, and that were associated with functional
disability, were included in this study. Functional disability was
assessed by a structured questionnaire containing dichotomous
questions (yes/no) about how the chronic syndrome had
interfered with their activities in the past 3 months, namely
with: (1) work; (2) responsibilities at home; (3) enjoyable
activities; (4) relationships; (5) personal goals; and (6) thinking
clearly, problem-solving, concentrating, or recall. To be included,
patients had to have at least one affirmative answer (i.e.,
Yes) to the questionnaire. Additionally, the Western Ontario
and McMaster Universities Osteoarthritis Index (WOMAC)
was used in the OA trial, as it is a reliable, and sensitive
instrument commonly used to assess pain and disability
in other studies of knee OA (Nunes et al., 2013). Only
OA subjects with a disability score on the WOMAC were
included.
Each clinical trial had rigorous inclusion criteria, and the
diagnoses were confirmed by a physician with over 15 years of
experience in chronic pain conditions. Specifically, the diagnosis
was determined by the presence of clinical complaints, current
and past medication, medical and psychiatric history, and
current medical and psychiatric diagnosis. Trials criteria are
summarized as follows:
1. Diagnosis criteria for chronic MPS included regional dull,
achy, or deep pain with normal neurological examination;
the presence of trigger or tender points, taut bands, palpable
nodules; and exacerbation by stress, which could involve
decreased range of motion and ropiness in the muscle
(Tough et al., 2007). To distinguish neuropathic pain
from ongoing nociception, the Neuropathic Pain Diagnostic
Questionnaire (DN4) was applied to all subjects. Only those
with a neuropathic component (score Z4) were included to
standardize the severity of MPS.
2. FM diagnosis adhered to 2010 American College of
Rheumatology criteria (Wolfe et al., 2011).
3. OA required the clinical and radiographic criteria of the
American College of Rheumatology.
4. Pain-free control volunteers were invited using media
advertisement and were prospectively recruited. We used a
standard screening questionnaire to assess if they fulfilled the
inclusion criteria. To be included, subjects had to be free of
any acute or chronic pain; without recent use of analgesics,
corticosteroids or medications with known effects on the
CNS. Also, volunteers were not included if had abused of
alcohol or psychotropic substances in the 6 months previous
to the screening; and if had any rheumatologic, psychiatric,
or neurological disorder. After obtaining written informed
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FIGURE 1 | CONSORT 2010 flow diagrams. The present cross-sectional study pooled baseline data from three clinical trials run at Hospital de Clínicas de Porto
Alegre (HCPA), and that recruited women with fibromyalgia (FM; NCT01904097), myofascial pain syndrome (MPS; NCT01964729), osteoarthritis (OA;
NCT01747070), and CSS indicates central sensitivity syndrome; VAS, visual analog scale.
consent, a structured interview, and a blood sample was
obtained. All biological samples were collected at the HCPA
in agreement with institutional policies. None of the healthy
volunteers underwent a thorough physical examination.
Although apparently a healthy population might have an
underlying disease, or asymptomatic tender points, the lack
of pain symptoms, or the lack of analgesics or other drugs
use in the last 6 months makes highly unlikely the presence
of current disease, particularly during the cross-sectional
evaluation of our study. None of the patients neither the pain-
free volunteers received monetary or any other compensation
for participating in the studies.
Dependent and Independent Variables of
Main Interest
The primary dependent variable was the measurement of
the SICI and the change on the numerical pain scale (NPS
0–10) during a heterotopic stimulus. Secondary outcomes
were other cortical excitability measures (MEP, SICF, and
CSP). The independent variables of primary interest were
the spectrum of structural pathology from persistent somatic
nociception (i.e., OA) to absence of tissue injuries such as
FM and MPS.
Instruments and Assessments
(a) The motor cortex excitability was assessed using TMS
with a MagPro X100 (MagVenture Company, Lucerne marked,
Denmark) and a figure-8 coil. The coil was centered over the
motor cortex (M1), held tangentially to the scalp to reach the
midline at 45◦. To ensure a relaxation of arms and correct
positioning of the hand, subjects were sat in a comfortable
reclining chair. Cortical excitability parameters were registered
through surface electromyography recordings gathered at the
contralateral right first dorsal interosseous muscles using
Ag/AgCl electrodes. First, the resting motor threshold (RMT)
was determined by obtaining five out of 10 consecutive trials
MEPs with a peak-to-peak amplitude of 50 µV. Next, 10 MEPs
were recorded with an intensity of 130% of the individual
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RMT. Moreover, the CSPs were assessed during muscle activity
measured on a dynamometer set to approximately 20% of the
maximal force. Accordingly, 10 CSPs were recorded using an
intensity of 130% of the RMT. The SICI was assessed using an
inter-stimulus interval of 2 ms. The conditioning stimulus (first)
was set at 80% of the RMT while the test stimulus (second)
was set at 100% of the individual MEP intensity. To assess the
SICF was used an inter-stimulus interval of 12 ms. In total,
30 trials of paired-pulse were conducted in a randomized order
(10 for each SICI, SICF, and control stimuli). We included the
collection of all amplitudes of the MEPs, SICI and SICF and the
duration of the CSPs in an off-line analyze. The units for these
parameters included MEP in mV, SICI and SICF in their ratio
to the MEP, and the CSP in milliseconds (Pascual-Leone et al.,
1994).
(b) Quantitative sensory testing (QST) was used to assess
heat pain thresholds using the method of limits with a computer
Peltier-based device thermode (30 × 30 mm; Schestatsky et al.,
2011). The thermode was attached to the skin on the ventral
aspect of the mid-forearm, with an increase of temperature at
a rate of 1◦C/s, from 30◦C to a maximum of 52◦C. We asked
the participants to press a button as soon as their felt mild
pain (6/10) on the NPS ranging from 0 (no pain) to 10 (the
worst pain). A single training session was offered before so
participants could get familiar with the device. The thermode
remained on the right ventral forearm, even though, it was
slightly altered on trials to avoid either response suppression
or sensitization of the cutaneous heat nociceptors. To evaluate
the degree to which pain perception is modulated following
the presentation of an initial heterotopic noxious stimulus
(CPM), we used the QST during cold water immersion. This
sensation was assessed raising the temperature to the point at
which subjects felt mild pain (6/10) on the NPS. Thus, they
immersed their non-dominant hands into cold water (zero to
four degree Celsius) for 1 min. The QST was administered
after 30 s of the cold-water immersion. During this time,
subjects were asked to rate the pain of the stimulated arm (pain
sensation by heat) using the same NPS. During the experiment
for each participant, the temperature was held constant. The
CPM was defined as the difference (presented in percentage)
between the average pain rating before and after cold water
immersion. To control for individual variation concerning
baseline values, we used the proportion of difference from
baseline.
Potential Confounding Factors
The psychological tests used in the current study had been
validated for the Brazilian population (Gomes-Oliveira et al.,
2012; Sehn et al., 2012). Two independent medical examiners
were trained to administer the pain scales and to conduct the
psychological tests. The patients’ depressive symptoms were
assessed using the Beck Depression Inventory II (Gomes-
Oliveira et al., 2012). The catastrophizing thinking related
to pain was evaluated using the Brazilian Portuguese of the
Catastrophizing Scale (B-PCS; Sehn et al., 2012). We used
a standardized questionnaire to assess demographic data and
medical comorbidities.
Serum Neuroplasticity Mediators’
Concentration
All of the trials used standard procedures for biological samples,
by collecting blood at minimum 8 h after fasting early in the
morning. All biological materials were collected before applying
any intervention. Plastic tubes were centrifuged for 10 min at
5000 g at 4◦C. Serum was frozen at −80◦C until assays were
performed. Serum neuroplasticity mediators concentrations
were determined using specialized BDNF kits (catalog no.
CYT306, the lower detection limit of the kit = 7.8 pg/mL,
Chemicon/Millipore).
Efforts to Address Potential Sources
of Bias
To reduce assessment bias only two researchers (MGT; WC)
with a practicing of the outpatient pain clinic at HCPA with
vast clinical expertise were responsible formaking the diagnostics
according to pre-specified criteria. Three evaluators with specific
training in performing TMS were responsible for all TMS
measures of cortical excitability. The same evaluators applied
clinical scales and performed the QST.
Sample Size
The power of the study was estimated based on type II and
type I error of 0.15 and 0.05 respectively and in anticipation of an
effect size (f 2 = determination coefficient) of 0.15 for themultiple
hierarchical regression analysis allowing for four predictors (the
Post hoc statistical power calculator for hierarchical multiple
regression: 461. A sample of 100 patients would detect an effect
size for correlations of 0.15, with a power of 93% at a 0.05
alpha level.
Statistical Analysis
To summarize the main characteristics of the sample we used
traditional descriptive statistics, and performed Shapiro-Wilk
tests to evaluate a normal distribution, we used Shapiro-
Wilk tests. We used ANOVA to compare continuous variables
with parametric distribution, and Chi-Square or Fisher’s
exact test for categorical variables. Variables not normally
distributed were log transformed for further inclusion into
regression models.
To compare each cortical excitability parameter (MEP, CSP,
SICI, SICF) among CPS (MPS, FM, OA) and healthy subjects
we used ANOVA. While an MANCOVA was used to compare
the relationship between the cortical excitability parameters as
dependent variables (MEP, CSP, SICI, SICF) and the spectrum of
structural pathology as a binomial independent variable (where,
OA represents ongoing tissue injury and FM and MPS grouped
together represent the absence of structural pathology). Another
MANCOVA model was used to assess the relationship between
the SICI and the CPM (dependent variables) with the BDNF,
according to the spectrum of structural pathology. Taking into
account that the pain severity, the age, the degree of depressive
symptoms, and the use of psychotropic medications differed
1http://www.danielsoper.com/statcalc3/calc.aspx?id
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between the pain syndromes and that these factors can affect
the biological process of BDNF secretion, we constructed an
adjusted index. A multivariate regression model controlled by
multicollinearity was used to obtain an adjusted index used as the
surrogate of the BDNF. We adjusted for multiple comparisons
using Bonferroni correction. Cohen’s f2 effect size was calculated
using an effect size calculator for multiple regressions given the
values of R2 [A-priori Sample Size Calculator for Hierarchical
Multiple Regression2]. The data were analyzed using SPSS
version 22.0 (SPSS, Chicago, IL, USA).
RESULTS
One hundred records were retrieved from three different trials
ran in the HCPA. The sample of CS syndrome without structural
pathology was composed of subjects with MPS (n = 54) and FM
(n = 19). The sample of CS syndrome with persistent nociceptive
input included subjects with OA (n = 27). The flow chart of this
study is presented in Figure 1.
We screened 123 potential participants with a diagnosis
of MPS, and 54 of them were included in the study.
Subjects were excluded if they did not fulfill the criteria
for MPS or due to the presence of another diagnosis
(e.g., FM). We screened 38 potential participants with a
diagnosis of FM, and 19 of them were included in the
study. Subjects excluded did not fulfill the diagnostic criteria
for FM or had other diagnoses (e.g., rheumatoid arthritis,
chronic use of corticosteroids). We screened 85 potential
participants with a diagnosis of OA, and 27 of them were
included in the study. We excluded them for not fulfilling
diagnostic criteria for severe OA, and due to the presence
of other diagnoses (i.e., surgery in the segment, chronic
use of corticosteroids, among others). We screened 27 HCs,
and 14 were included in the study. They were excluded
in the presence of depressive symptoms in moderate to
severe intensity, history of epilepsy, chronic headache or use
of psychotropics. Final sample characteristics are presented
in Table 1.
Motor Cortex Excitability Parameters
According to Chronic Pain Syndromes
The cortical excitability parameters are presented in Table 2. The
mean (SD) between CPS and healthy subjects were compared
using ANOVA followed by Bonferroni adjustment for multiple
comparisons. Compared to healthy volunteers, subjects with
MPS presented greater corticospinal tract excitability as shown
by elevated MEPs. They also exhibited higher SICF but reduced
SICI and CSP. As a matter of fact, MPS showed the largest
MEPs amplitude among the subjects with CPS. Furthermore, the
SICF was higher, while the SICI and CSP were lower in MPS
compared to healthy volunteers. Except the MEP, the cortical
excitability parameters of the MPS subjects were similar to those
with FM, but different to those of OA subjects. Except for
MEPs, FM subject’s cortical excitability was different to those
of the HCs in the same direction as MPS were. Likewise, the
2http://www.danielsoper.com/statcalc
cortical excitability parameters of the subjects with OA differed
to the one of the HCs in the same direction as MPS and FM,
which means having higher MEPs and SICF and lower SICI and
CSP.
Cortical Excitability According to the
Spectrum of Structural Pathology to
Absence of Tissue Injury
The multivariate regression model with the cortical excitability
parameters as dependent variables (MEP, SICF, SICI, CSP)
using the spectrum of structural pathology to an absence of
tissue injury as independent binomial variable, where structural
pathology (i.e., OA) is one level, and the absence of tissue
injury (MPS and FM pooled together) is the other level (please
see Table 3). This analysis showed a significant relationship
between the spectrum of structural pathology to an absence
of tissue injury and SICI (Wilks’ λ = 0.93, F = 3.16 (2)
= 85, P < 0.04). The power of this analysis was 0.80.
Subjects with an absence of structural pathology presented
greater disinhibition than those with persistent nociceptive
input. The adjusted mean (SD) on the SICI observed in the
absence of tissue injury was 56.36% lower than in those
with persistent nociceptive input [0.31(0.18) vs. 0.55 (0.32)],
respectively.
Relationship Between Intracortical
Inhibition and Descendent Pain
Modulatory System with The BDNF
According to Structural Pathology
The lack of significant differences in cortical excitability
parameters between MPS and FM supports the hypothesis that
both pathologies do not differ significantly in their cortical
facilitatory and inhibitory profile. Therefore, FM and MPS
were grouped under the label of CSS with an absence of
tissue injury for the subsequent analysis. As presented in
Table 1, serum BDNF differs between healthy volunteers and
subjects. When pooling subjects according to the presence of
tissue injury, we observed that serum BDNF in those with
the spectrum of structural pathology had significantly lower
levels in comparison to those with absence of tissue injury,
with 17.91 (7.27) and 35.29 (21.22), respectively (t = 3.830;
P < 0.0001 of the comparison after log transformation of both
serum BDNF). To account for the influence of pain severity,
age, depressive symptoms, and use of psychotropic medications
on the secretion of BDNF, an index was constructed using
multivariate regression. The factors included explained 30% of
the variance of the model.
The multivariate linear regression model included the
SICI and the CPM as dependent variables, and the used as
independent variables the structural pathology (absence vs.
presence, binomial) and the BDNF adjusted index. The model
is presented in Table 4. This analysis showed a significant
relationship between the presence of structural pathology, the
SICI and the CPM (Wilks’ λ = 0.90, F = 4.83, P < 0.01).
The power of this analysis was 0.81. Subjects with an absence
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TABLE 1 | Characteristics of the sample.
Characteristic Healthy Myofascial pain Fibromyalgia Osteoarthritis P
subjects syndrome (n = 19) (n = 27)
(n = 14) (n = 54)
Age (years) 32.43 (10.81) 46.13 (12.10) 50.42 (8.84) 64.42 (7.81) 0.00
Body mass index (kg/m2) 23.12 (2.93) 25.22 (4.37) 31.81 (7.08) 28.52 (5.52) 0.00
Years of education 17.14 (2.53) 10.16 (3.61) 13.29 (4.04) 10.37(5.61) 0.00
Employed (yes/no) 14/0 45/9 16/3 19/8 0.19
Smoking (yes/no) 0/14 2/52 5/14 0/27 0.14
History of psychiatric disorder (yes/no)∗ NA 19/35 7/12 5/22 0.24
Drug active on the nervous system (yes/no)∗∗ NA 17/37 11/8 12/15 0.11
Tricyclic antidepressant (yes/no) NA 7/47 7/12 1/26 –
Selective serotonin reuptake inhibitor (yes/no) NA 8/46 9/10 6/21 –
Anticonvulsants (yes/no) NA 4/50 1/18 0/27 –
Benzodiazepine NA 1/53 2/17 5/22 –
Chronic disease (yes/no) NA 11/8 16/38 20/7 0.00
Hypertension (yes/no) NA 14/40 10/9 14/13 –
Diabetes mellitus (yes/no) NA 5/49 1/18 4/23 –
Asthma (yes/no) NA 1/53 3/16 3/24 –
Number of analgesic doses used per week (≥4 doses-week/<4 doses) NA 27/26 14/5 20/6 0.04
Pain on the VAS (last 7 days) NA 7.23 (2.19) 7.94 (1.89) 6.26 (2.15) 0.03
Pain on the VAS (24 h) NA 6.11 (2.59) 7.10 (1.88) 5.37 (2.47) 0.06
Beck depression inventory II NA 13.92 (8.85) 24.47 (11.67) 10.04 (7.18) 0.00
Brazilian portuguese catastrophizing scale (B-PCS) NA 28.26 (12.51) 34.68 (11.69) 22.89 (11.59) 0.00
Serum BDNF (ng/mL) 19.00 (8.79) 29.28 (20.01) 50.78 (16.06) 17.91 (7.27) 0.00
Data are presented as mean (standard deviation) or number of subjects (n = 114). ∗Patients could have none or more than one psychiatric disorder. ∗∗Some patients were
using more than one type of drug. Abbreviations: visual analog scale for pain, from 0 to 10 (VAS); brain-derived neurotrophic factor (BDNF).
of structural pathology presented greater disinhibition than
those with persistent nociceptive input. The increase in BDNF
was associated with the lower efficiency of the descendent
pain modulatory system. However, it was not observed any
difference of the BDNF effect in the SICI when we compared it
according to the presence of tissue injury. Thus, to address this
important issue we conducted an additional regression analysis
to assess the relationship between the SICI and BDNF despite the
condition sustaining pain. This model revealed a β coefficient
= −0.22; t = −2.14; P = 0.03, suggesting that the relationship
between BDNF and ICI is independent of the chronic pain
mechanism.
Figures 2A,B presents the relationships between the
SICI and the CPM (primary outcomes) according to the
presence of structural pathology. The means were compared
using MANCOVA, and post hoc were adjusted for multiple
comparisons using Bonferroni correction (themodel is presented
in Table 4).
TABLE 2 | Cortical excitability parameters presented by chronic pain syndrome (CPS).
Chronic pain syndrome
Fibromyalgia Myofascial pain Osteoarthritis Healthy subjects
(n = 19) syndrome (n = 54) (n = 27) (n = 14)
Motor evoked potential (mV) 1.13 (0.11)a 1.64 (0.49)c 1.46 (0.62)b 1.25 (0.38)a
Short intracortical facilitation 0.96 (0.44)c 1.13 (0.23)c 0.97 (0.41)c 0.71 (0.36)a
(ratio: SICF/test stimulus)
Short interval intracortical inhibition 0.32 (0.22)c 0.31 (0.17)c 0.59 (0.30)b 0.92 (0.07)a
(ratio: SICI/test stimulus)
Cortical silent period (CSP) 68.07 (18.43)c 68.44 (20.55)c 62.20 (16.68)b,c 76.67 (21.35)a
Data are presented as mean (SD; n = 114). Different superscripts (a, b, c) indicate significant difference among treatment groups after post hoc analysis adjusted by
Bonferroni (P < 0.05). Analysis of variance (ANOVA) to compare mean (SD).
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TABLE 3 | Relationship between motor cortex excitability according to the spectrum of structural pathology and absence of tissue injury (n = 100).
Dependent variable Type III df Mean F P Partial eta
sum of squares square error squared
Motor-evoked-potential amplitude (mV) 2.10 2 1.05 4.11 0.02 0.09
Short intracortical facilitation (ratio: SICF/test stimulus) 0.19 2 0.09 0.86 0.42 0.02
Short interval intracortical inhibition (ratio: SICI/test stimulus) log 5.42 2 2.71 7.42 0.001 0.15
Cortical silent period (CSP) 2668.54 2 1334.27 3.55 0.03 0.08
B SEM t P Partial eta
squared
Motor evoked potential (mV)
Intercepted 2.06 0.37 5.64 0.000 0.27
Absence of structural pathology (n = 73) −0.008 0.17 −0.05 0.96 0.00
Presence of structural pathology (n = 27) 0a – – – –
Age (years) −0.01 0.005 −2.27 0.02 0.06
Short intracortical facilitation (ratio: SICF/test stimulus)
Intercepted 1.05 0.24 4.30 0.000 0.18
Absence of structural pathology (n = 73) 0.09 0.11 0.81 0.41 0.008
Presence of structural pathology (n = 27) 0a – – – –
Age (years) −0.001 0.003 −0.30 0.76 0.001
Short intracortical inhibition (ratio: SICI/test stimulus) log
Intercepted −0.79 0.43 −1.82 0.07 0.00.
Absence of structural pathology (n = 73) −0.58 0.20 −2.84 0.006 0.09
Presence of structural pathology (n = 27) 0a – – – –
Age (years) 0.002 0.006 0.27 0.79 0.001
Cortical silent period
Intercepted 68.74 14.03 4.89 0.001 0.22
Absence of structural pathology (n = 73) 8.60 6.54 1.31 0.19 0.02
Presence of structural pathology (n = 27) 0a – – – –
Age (years) −0.19 0.19 −0.99 0.32 0.01
DISCUSSION
This study assessed the motor cortex excitability by using
different TMS measures, such as MEP, CSP, SICI, SICF,
and BDNF levels in chronic musculoskeletal pain according
to structural pathology. These data suggest that there is
a relationship between the motor cortex disinhibition and
conditions of chronic musculoskeletal pain compared to healthy
subjects. This disinhibition is greater in subjects with chronic
pain without tissue injury compared to the ones with structural
lesion (Table 4). Additionally, after adjusting for relevant
confounders, higher levels of BDNF were significantly correlated
with decreased inhibitory system as assessed by CPM.
We observed greater disinhibition at the cortical level when
the CS syndrome occurred without evidence of structural
pathology (i.e., MPS and FM) compared to those with persistent
nociceptive input (i.e., OA). This finding suggests that a different
activation of the nociceptive system leads to distinct plastic
changes in the pain pathways. It is possible that this disinhibition
process is a common feature of CPS, which could be further
increased in the absence of structural pathology due to lack of
opposition. Furthermore, the cortical inhibition could be used as
an additional tool to infer, to a certain extent, the level of severity
of the CS phenomena. This needs, however, further confirmation
with large clinical trials.
This hypothesis is biologically plausible because the
disinhibition results from the imbalance between excitability and
inhibition induced by GABA activity reduction, an increase in
glutamate activity, and activation of NMDA-dependent activity
(Nitsche et al., 2010). These dysfunctions in excitatory/inhibitory
systems at pain pathways are nothing but the biological grounds
of the clinical picture known as CSS.
Our study suggests that the supraspinal reorganization in
different chronic musculoskeletal pain conditions, which is in
agreement with previous studies (Gracely et al., 2002; Flor,
2003). Despite being conceivable that due to the structural lesion,
pain occurs by specific activation of pain pathways, a sustained
activation of the nociceptive system leads to an involvement
of different brain circuitries. While in the CS syndromes in
the absence of an obvious source of nociception, a self-driven
stimulus activates the pain circuits autonomously. Thereby,
the present findings suggest the evidence for a disinhibition
spectrum that was presented according to the pathophysiology
of chronic musculoskeletal pain.
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TABLE 4 | Relationship between intracortical inhibition and descendent pain modulatory system with the brain-derived neurotrophic factor (BDNF)
according to the spectrum of structural pathology and absence of tissue injuries (n = 100).
Dependent variable Type III df Mean F P Partial eta
sum of squares square error squared
Change of NPS (0–10) during CPM-task 73.097 3 24.36 4.60 0.005 0.30
Short intracortical inhibition (log) 3.88 3 1.29 3.75 0.014 0.11
B SEM t P Partial eta
squared
Change of NPS (0–10) during CPM-task
Intercepted 0.10 0.69 0.16 0.880 0.00
Absence of structural pathology (n = 73) 4.46 0.76 5.90 0.001 0.28
Presence of structural pathology (n = 27) 0a – – – –
BDNF (adjusted index) −0.09 0.03 −3.02 0.003 0.09
Interaction
Absence of structural pathology vs. BDNF −0.07 0.03 −2.31 0.020 0.06
(index adjusted; n = 65)
Presence of structural pathology vs. BDNF −0.29 0.07 −4.33 0.001 0.18
(index adjusted; n = 27)
Short intracortical inhibition (log)
Intercepted −0.80 0.18 −4.55 0.001 0.19
Absence of structural pathology (n = 73) −0.45 0.19 −2.34 0.020 0.06
Presence of structural pathology (n = 27) 0a – – – –
BDNF (index adjusted) 0.00 0.008 0.05 0.95 0.00
Interaction
Absence of structural pathology vs. BDNF −0.001 0.003 −0.29 0.78 0.001
(index adjusted; n = 65)
Presence of structural pathology vs. 0.01 0.006 1.77 0.08 0.04
BDNF (index adjusted; n = 27)§
§Take in account that the severity of pain, age, depression symptoms, and use of psychotropic medication as dummy variable.
Our data also shows that the neuroplastic changes as
assessed by the TMS measurements were related to both,
the musculoskeletal CPS and its severity (interpreted as the
gradient in evident structural pathology). An indirect evidence
supporting these claims is that there are morphometric
differences in prefrontal and thalamic gray matter between
subjects with neuropathic and non-neuropathic chronic
pain, which can suggest differential CNS neuroplasticity
according to the etiology involved in the development of
chronic pain (Apkarian et al., 2004). Also, corresponding
neuroplastic changes were experimentally observed in a
transient deafferentation-induced by an anesthetic nerve
block (Theuvenet et al., 2011). Taken together, these findings
suggest that the pathophysiological mechanisms and the
severity of the disease moderate the disinhibition process.
This hypothesis is also supported by further evidence in
neuropathic pain, in which a more pronounced motor
cortex disinhibition was observed in the moderate/severe
pain (NRS ≥ 4) compared to the mild pain. The cortical
reorganization has also been suggested following the use of
rTMS applied to the motor cortex restored the equilibrium
between the excitatory and inhibitory system in parallel to the
reduction in pain intensity (Lefaucheur et al., 2006; Mhalla
et al., 2011). Moreover, increased ICF and a decreased SICI
in the contralateral hemisphere following limb amputation
was shown (Chen et al., 1998; Schwenkreis et al., 2000),
thus supporting a cortical reorganization. Likewise, subjects
with complex regional pain syndrome (CRPS) presented
a reduced SICI, not only in the ipsilateral but also in the
contralateral motor cortex (Lenz et al., 2011). Similarly,
SICI reduction was shown in several other different chronic
pain conditions, such as MPS (Dall’Agnol et al., 2014),
FM (Mhalla et al., 2010), OA (da Graca-Tarragó et al.,
2015) and neuropathic pain syndromes (Schwenkreis et al.,
2010).
The cortical excitability pattern of FM and MPS is not
significantly different. The only difference is in the MEPs,
which is thought to represent the corticospinal tract excitability
(Petersen et al., 2003). In fact, these two entities might be
the same syndrome, which represents a continuum at different
moments at long of time. According to other authors have
previously proposed such interpretation, although they offered
scarce evidence supporting this point (Ge et al., 2009).
In the present study, the heterotopic nociceptive stimulus
during the CPM-task induced a greater response in the
descending modulatory system in subjects with persistent
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FIGURE 2 | Mean and standard error of mean (SEM). (A) Change on
numerical pain scale [NPS (0–10)] during conditioned pain modulation
(CPM)-task; (B) Short intra-cortical inhibition (SICI) expresses the relationship
between the amplitude of wave and motor evoked potentials (MEPs) (relative
amplitude, express in %), at inter-stimuli intervals (ISIs) of 2 ms with
paired-pulse. The first is a sub-threshold stimulus [80% of the rest motor
threshold (rMT)] followed by the second one which is a suprathreshold
stimulus (130% rMT). Spectrum of structural pathology to absence of tissue
injury to persistent nociceptive input. The error bars indicate the SEM. An
asterisk indicates a significant difference between groups according to
spectrum of structural pathology to absence of tissue injury to persistent
nociceptive (P < 0.05). A MANCOVA was used to perform the comparisons,
followed by the Bonferroni correction for post hoc multiple comparisons.
nociception compared to an absence of tissue injury. Although
the mechanisms underlying this phenomenon are unknown,
it is known that during inflammation the periaqueductal gray
(PAG) suffers structural changes (Guan et al., 2002; Miki et al.,
2002; Imbe et al., 2005). Furthermore, in the spinal cord,
an increased turnover of noradrenaline (Weil-Fugazza et al.,
1986) and the number of alpha(2)-adrenergic receptor has been
associated with the inflammation (Brandt and Livingston, 1990).
All these changes likely contribute to a rise in descending pain
inhibition. It is possible that the inflammation contributes to
triggering and maintenance of increased inhibitory controls.
However, there are mixed results. Chronic arthritis induced
experimentally strengthens the excitatory drive caused by
conditioning stimulus (Danziger et al., 1999). Whereas in clinical
studies subjects with FM presented a reduction of CPM, which
potentially contributes to hyperalgesia (Kosek and Hansson,
1997) and in neuropathic pain the effect of CPM varied from a
particular influence on on-going vs. evoked pain (Witting et al.,
2003).
Although the mechanisms of facilitation induced by chronic
pain prompt to disengagement in the descending modulation,
according to the present findings this process can have
a distinct level of severity according to the spectrum of
structural pathology to an absence of tissue injury. The
descendent modulation involves some mechanisms to inhibit
the neurotransmission at the PAG, and at the spinal cord.
These mechanisms include the activation of inhibitory of
interneurons (Millar and Williams, 1989); reduction the
quantity of amino acids, neuropeptides, and monoamines
(Jensen and Yaksh, 1984); and postsynaptic inhibition of pain-
relay neurons (Giesler et al., 1981). Additionally, the role of
monoamines in order to increase the inhibition has already
been demonstrated in preclinical studies, in which the duloxetine
use reduces the amine uptake (Wong et al., 1993), and also
in clinical research (for instance in knee OA), where the
duloxetine decreased pain more than placebo (Chappell et al.,
2009).
In this report, the reduced inhibition was inversely correlated
with the BDNF despite the pain condition. This result
highlights the remarkable effect of this neurotrophic factor in
the cortical neuroplasticity process. Equally, the BDNF had
an inverse correlation with the CPM, thus suggesting that
decreased function in the descending pain modulatory system
(greater scores in the CPM) prone to a higher propensity for
pain. In this way, we showed that the variability of serum
BDNF and the dynamic state of inter-hemispheric cortical
excitability was independent of the mechanism underlying the
chronic musculoskeletal pain. Thus, the correlation between
the disinhibition in the motor cortex and the dysfunction of
descending pain modulation system observed in this study
might have clinical relevance because the CPM is a marker
with a large size effect to identify impairment of descendent
pain modulatory system in populations with long-term pain
conditions (Lewis et al., 2012). Hence, it is biologically
plausible that the BDNF enhancement activates signaling
pathways in the spinothalamic tract due to a reduction of
the GABAergic inhibitory effect (Spezia Adachi et al., 2015).
Even so the design of this study prevents establishing if
the disinhibition in the motor cortex could result in the
higher serum levels of this neurotrophic factor, or vice-
versa, it does permit us to a better comprehension of
the dysfunctional disinhibition at cortical and intra-cortical
regions in severe musculoskeletal chronic pain. Thereby, the
pieces of evidence these findings possess may hold clinical
implications such as to understand that the effects of BDNF
in GABAergic/glycinergic system engage multiple molecular
and cellular mechanisms that are largely complementary
(i.e., increased excitation and reduced inhibition) in spinal,
midbrain and peripheral structures associated with nociceptive
processing. The secretion of BDNF by microglia downregulates
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of the Cl-cotransporter K+-Cl− exporter (KCC2) expression
in the dorsal horn resulting accumulation of intracellular
chloride shifts the chloride equilibrium potential (ECl) to
a less negative value. Hence, the activation of GABAA
receptors produces a less hyperpolarization and a less inhibition
(Prescott and De Koninck, 2005; Prescott et al., 2006). If
ECl is sufficiently displaced, GABA may exert an excitatory
effect and augments nociceptive transmission at the level of
descending control mechanisms by a tyrosine receptor kinase
B (TrkB)-dependent mechanism (Guo et al., 2006). In fact,
there is compelling evidence that BDNF is a ubiquitous
pain mediator at many levels of the nervous system. Given
this, it is hard to conclude that the generation of BDNF is
indeed a compensatory mechanism specifically associated with
both, chronic inflammatory and neuropathic pain. So, these
results support the hypothesis that the chronic pain induces
reorganization in circuits involved in pain processing at cortical
and in descending pain modulatory system. Also, they suggest
that the pain thresholds are in opposite direction of BDNF level
in severe chronic musculoskeletal pain independently of the pain
mechanism.
However, several potential limitations in this study need
to be addressed. From a biological perspective, the integration
of cortical excitability, descendent modulatory system, and
neuroplasticity makers has been showed in conditions other
than pain, including inflammation, cancer, learning, memory,
epilepsy, neurodegenerative, and neuropsychiatric disorders.
Therefore, differences among different populations deserve
additional consideration. Furthermore, a set of factors such
as pain severity, age, analgesic and antidepressant use and
depressive symptoms differed between our samples. As we
demonstrated in a previous study, BDNF is a marker to
distinguish to some extent the level of CS among several
types of non-neuropathic chronic pain (Deitos et al.,
2015). In previous studies, an association between BDNF
levels and cortical excitability measures was shown (Kleim
et al., 2006; Cheeran et al., 2008). In fact, in the clinical
setting is not possible to assess directly and isolate the
effect of each one of these potential confounding factors
in the BDNF secretion, neither in the neurophysiological
measures. Thus, to control for the potential concealed
influence of these set of factors in the BDNF secretion
and in the measures of cortical excitability we constructed
an adjusted index. This approach allows us to evaluate
the contribution of BDNF as the independent variable on
the cortical excitability (SICI) and in the descending pain
modulatory system function on a standard scale. To the best
of our knowledge, the relationship between BDNF, cortical
excitability, descending pain modulatory system and the
mechanism of musculoskeletal pain syndrome have not been
explored before. But the cross-sectional nature does not allow
establishing a cause-effect relationship. Nonetheless, this is
certainly a good starting point to generate hypotheses for
future studies. Also, the present results should be carefully
considered in male samples because BDNF levels seem
to be sex-dependent (Stefani et al., 2012). Moreover, the
chronic pain samples studied in this study do not (neither
pretend) represent all cases of CS syndromes, such as
neuropathic pain and disorders with little pain involvement
(e.g., conditions with less structural involvement, such as
hand OA).
The aim of this study, was to comprehend the changes
associated with the CSS in the neurophysiological and
neurobiological measures. Thus, from a musculoskeletal
pain perspective, the MPS in initial stages may be triggered
by peripheral nociceptor stimuli, which will induce changes
in brain networks, which in turn will begin to generate
self-inputs to sustain the pain sensation (Mense, 2010).
Therefore, to reduce the heterogeneity in the sample with
the absence of peripheral nociception, only subjects with
MPS that had a neuropathic component and functional
disability were initially included. Significant cortical alterations
have already been demonstrated in this sample by our
group, in which increased intracortical facilitation and a
dysfunction in the descendent pain system was observed
(Dall’Agnol et al., 2014). In fact, it is possible that the chronic
pain syndrome with an absence of nociception tends to
induce more disinhibition by the lack of contra-regulatory
effects induced by the sustained nociception. Thus, from
a clinical perspective, the classification of CSS according
to the spectrum of tissue injuries provides a substrate for
rehabilitation, because it was shown that CSS subjects with
an absence of nociception current worst catastrophizing
thinking related to pain (Soriano-Maldonado et al., 2015).
Hence, therapeutic approaches could then also change
maladaptive illness beliefs, and thus altering maladaptive
pain cognitions. This can help in the clinical decision process,
as well as helping in the construction of practical approaches
for ‘‘unexplained’’ chronic musculoskeletal pain for both,
clinical recognition (Nijs et al., 2010) and treatment (Nijs
and Van Houdenhove, 2009; Nijs et al., 2010). Specifically,
CSS therapies could target the neuroplasticity process using
pharmacological (i.e., antidepressant, anticonvulsant, etc.) and
non-pharmacological techniques such as transcranial direct
current stimulation (tDCS), TMS, electro-acupuncture and
other physical and cognitive therapies.
Also, in the present study, the serum level of BDNF can
overestimate the central sources because we cannot isolate
its source of other structures besides the brain. In this way,
a recent study showed BDNF gene in primary cultures of
megakaryocytes of rats and human, which suggests that the
platelets could represent the largest source of BDNF (Chacón-
Fernández et al., 2016). In spite of this; it has also been
demonstrated, that the circulating BDNF represents 70–80% of
the one produced in the CNS (Rasmussen et al., 2009). Also,
an experimental study in rats showed a correlation of about
0.8 between the serum levels of BDNF and its concentration in
the cerebral cortex (Karege et al., 2002). Although the transport
of BDNF produced in the CNS occurs through the blood-
brain barrier (BBB) via saturable systems, this data suggests
that the fluctuations of this neurotrophin in the blood reflect
changes in the nervous system (Poduslo and Curran, 1996;
Asmundson et al., 1999). Furthermore, there are a significant
number of studies demonstrating that occur variations in the
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serum levels of BDNF after interventions with effect in the
CNS (Okamoto et al., 2008; Solati et al., 2015; Jeong et al.,
2016; Kawazu et al., 2016; Niimi et al., 2016; Wens et al.,
2016). These approaches therapeutics include antidepressant
drugs (Brunoni et al., 2008), electroconvulsive therapy (ECT;
Brunoni et al., 2014), TMS (Dall’Agnol et al., 2014) and tDCS
(Brietzke et al., 2015). Haile et al. (2014) demonstrated similar
results post-infusion of ketamine, where they observed a higher
increase in serum levels in responders compared to non-
responders. Thus, this set of evidence shows that changes in
peripheral BDNF levels are associated with clinical outcome
involving a neuroplasticity process, and they suggest that at
least part of BDNF is produced in CNS. Nevertheless, we
should have parsimony in the interpretation these results
because we can infer only indirectly changes of BDNF from the
brain.
In sum, the present findings showed greater disinhibition in
the motor cortex and the descending inhibitory pain modulation
system in FM and MPS than in OA. Likewise, the inter-
hemispheric disinhibition as well as the dysfunction in the
descending pain modulatory system is higher in chronic pain
with the absence of tissue injury compared to chronic pain
with a structural lesion. Finally, increased level of serum BDNF
mediated the disinhibition of motor cortex excitability, as well as
the function of descending inhibitory pain modulation system,
independently of the physiopathology mechanism involved in
these musculoskeletal pain syndromes.
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